Phase 3 Infectious Disease Study: 42% Cohort Enrollment Across 36 States in Just 8 Weeks Science 37 was the top enrolling site, contributing 42% of total participants across 36 states…
Delivering 25% of Total Enrollment for a Phase 3 Rare Disease Trial Science 37 was the top enrolling site, contributing 25% of all randomized patients nationwide. Through…
Delivering 28% of Total Enrollment for a Phase 3 Respiratory Trial Science 37 was the top enrolling site, contributing 28% of total enrolled patients over a…
Enrolling 55% of Total Participants for a Phase 3 Neurology Trial Science 37 was the top enrolling site, enrolling 55% of total study participants and achieving…
Enrolling 47% of Total U.S. Participants for a Phase 3 Hepatology Trial Science 37 was the top enrolling site, contributing 47% of total U.S. study participants. Despite…
How to Operationalize Respiratory Clinical Trials with the Direct-to-Patient Site Are you looking to expand patient access for your respiratory clinical trials? Discover how a…
Science 37 Enables Real-Time Data Collection in Phase 4 Study A top pharma sponsor approached Science 37 to conduct a Phase 4 clinical trial for…
Science 37 Delivers 96% Patient Retention in Fully Remote Study Science 37 conducted a fully decentralized trial for patients with systemic lupus erythematosus and sjogren's…
Science 37 Delivers Diverse Patient Enrollment in Respiratory Clinical Trial In a study for a respiratory syncytial virus (RSV) vaccine, Science 37 was contracted to…
Science 37 Accelerates Enrollment for Dermatology Clinical Trial A biopharma company was conducting a Phase 2 randomized controlled trial in the United States…
Science 37 Launches Infectious Disease Prevention Study in Just 12 Weeks A biotech sponsor contracted Science 37 to help enroll patients in a global Phase 2/3…
Science 37 Accelerates Oncology Clinical Trial Timeline by 3 Years A biopharma company was investigating how its diagnostic screening technology—a one-time blood sample—performed against the…
